"A vaccine against one of the most neglected yet fatal tropical diseases is being tested for the first time in a clinical trial in India and the U.S.," IRIN reports. Visceral leishmaniasis (VL), "also called kala-azar or black fever, infects an estimated half million persons or more annually," and "it ...

The Infectious Disease Research Institute (IDRI) has launched the first human trial of a new vaccine for Visceral Leishmaniasis (VL). The trial is being conducted in Washington State, and a Phase 1 trial is planned in India, where VL is prevalent. The IDRI is a Seattle-based nonprofit that develops ...

Seattle, WA | February 22, 2012 -- The first clinical trial of a new vaccine for visceral leishmaniasis (VL) has been launched by the Infectious Disease Research Institute (IDRI), a Seattle-based nonprofit that develops products to prevent, detect, and treat diseases of poverty. The Phase 1 trial is taking place ...

(Infectious Disease Research Institute) Seattle's Infectious Disease Research Institute is launching dual Phase 1 clinical trials in Washington State and India in test of the first ever vaccine to prevent visceral leishmaniasis (VL). The trials are a milestone toward halting a disease with a 90 percent fatality rate within two ...

Researchers at the University of Dundee have identified fexinidazole as a possible, much-needed, new treatment for the parasitic disease visceral leishmaniasis. Leishmaniasis is named after William Leishman, a Glasgwegian doctor serving with the British Army in India, who first identified the parasite in the early 1900s. The disease is the ...

Researchers at the University of Dundee have identified fexinidazole as a possible, much-needed, new treatment for the parasitic disease visceral leishmaniasis. Leishmaniasis is named after William Leishman, a Glasgwegian doctor serving with the British Army in India, who first identified the parasite in the early 1900s. The ...

(Medical Xpress) -- A study published yesterday shows that a drug called fexinidazole could potentially be used to treat visceral leishmaniasis, a parasitic disease that kills 50 000 to 60 000 people a year in Africa, Asia and Latin America.

(University of Dundee) Researchers at the University of Dundee have identified fexinidazole as a possible, much-needed, new treatment for the parasitic disease visceral leishmaniasis.

Gilead Sciences, Inc. "will donate 445,000 vials of AmBisome over five years to help the World Health Organization (WHO) treat more than 50,000 patients with visceral leishmaniasis (VL), also known as kala-azar," a Gilead press release states, adding, "If sold at Gilead's no-profit access price, today's donation would cost more ...

Leishmaniasis is a serious parasitic disease with several forms, cutaneous mucocutaneous or visceral, respectively causing skin sores, ulceration and internal damage. The visceral form can be fatal if no treatment is given. These diseases are endemic in more than 98 countries across the world, most of them developing countries, and ...

IRD scientist and their research partners recently identified the key role of nicotinamidase, an enzyme in the parasite Leishmania, essential for its survival but which does not exist in humans. The pathogen is incapable of developing in mammals In the absence of this enzyme. Specific targeting of this enzyme could ...

A significant step towards understanding the genetic make-up of a parasite which causes leishmaniasis - a flesh-eating disease spread by the bite of a female sand fly - has been made by a team of researchers from the University of Glasgow. The study is published in the journal Genome ...